Aurolab aqueous drainage implant implantation made easy: A video-based step-by-step guide

Background: Glaucoma is one of the major causes of irreversible blindness in the world, with trabeculectomy still being the primary surgical modality for the management of glaucoma. Glaucoma drainage devices (GDDs) have been conventionally used for the treatment of refractory glaucoma and are found to be beneficial in eyes with prior unsuccessful filtration surgeries and primary choice of surgery in certain glaucoma. Aurolab aqueous drainage implant (AADI) is a nonvalved device useful in refractory glaucoma to achieve low intraocular pressure (IOP). The device has been commercially available in India since 2013 and is like the Baerveldt glaucoma implant in design and function. AADI being the most economical and effective GDD in controlling IOP is becoming a popular choice among ophthalmologist in developing countries. AADI surgery has steep learning curve due to large end?plate surface area which needs a rigorous conjunctival dissection, muscle hooking, meticulous plate fixations, and careful tube ligations and insertion. There are different techniques of performing AADI surgery, but the authors have tried to simplify the complex surgery for easy and catchable learning of the procedure by novice surgeon with their experience and have elaborated a step?wise most effective way of performing surgery. Purpose: This video?based skill transfer depicts steps of AADI surgery with compilation of various modifications and authors’ tips and tricks to novice surgeons. Synopsis: This video depicts detailed steps of AADI surgery with micro?points and authors experience. Video also shows various tailor?made modifications of surgical techniques for different case scenarios. Highlights: Steps of AADI surgery, modifications, and surgical pearls.

Incidence, outcomes, and risk of surgical failure after development of early hypotony following Aurolab aqueous drainage implant surgery

Purpose: To report the incidence, outcomes, and risk of surgical failure after early postoperative hypotony following Aurolab Aqueous Drainage Implant (AADI) surgery for adult and pediatric refractory glaucoma. Methods: Medical records of patients who underwent AADI between January 2013 and March 2017 with a minimum of 2?years follow?up were retrospectively reviewed. Early postoperative hypotony was defined as IOP ?5 mmHg within the first 3 months after AADI. Surgical failure of AADI was defined as IOP >21 mmHg or reduced <20% below baseline on two consecutive follow?up visits after 3 months, IOP ?5 mmHg on two consecutive follow?up visits after 3 months, reoperation for glaucoma or a complication, or loss of light perception vision. Results: Early postoperative hypotony was seen in 15/213 eyes (7%) in the adult group and in 6/101 eyes (6%) in the pediatric group. The onset of hypotony was significantly earlier in the pediatric group (median = 39 days post AADI, IQR = 20–58 days) compared with adult eyes (median = 51 days post AADI, IQR = 30–72 days) (P = 0.02). Eyes with early postoperative hypotony did not have an increased risk of cumulative surgical failure as compared with eyes without hypotony in both adult (33.3% vs. 23.7%; P = 0.48) and pediatric (33.3% vs. 13.7%; P = 0.16) refractory glaucoma. All eyes recovered from hypotony, though one adult eye developed retinal detachment and one pediatric eye developed corneal decompensation and lost vision. Conclusion: Early postoperative hypotony was an infrequent complication post AADI and occurred earlier in pediatric eyes. Early postoperative hypotony did not increase risk of surgical failure up to 2 years.

Short-term outcomes of micropulse transscleral cyclophotocoagulation as a primary versus additional therapy in eyes with uncontrolled glaucoma

Purpose: To study the safety and efficacy outcomes of Micropulse Transscleral Cyclophotocoagulation (MP?TSCPC) as a primary versus additional therapy in eyes with uncontrolled glaucoma. Methods: This was a prospective, interventional, comparative study. All patients with advanced and refractory glaucoma treated with MP?TSCPC from April 2020 to December 2020 were recruited in this study. Results: A total of 77 eyes of 77 patients were analyzed. Group A (n = 33), included patients with advanced glaucoma at high risk for invasive surgery, who underwent MP?TSCPC as the primary intervention, and group B (n = 44) included patients who had undergone previous surgical intervention and MP?TSCPC was used additionally to control the intraocular pressure (IOP). Mean IOP and mean number of antiglaucoma medications were 34.06 (13.9) mmHg and 3.64 (0.7), respectively, in group A and 35.61 (11.5) mmHg and 3.73 (0.9), respectively, in Group B. Postoperatively, the mean IOP and percentage of IOP reduction were significantly lower at 1, 3, and 6 months, that is, 20.78 (32%), 22.07 (30%), and 19.09 (37%), respectively, in group A and 23.68 (35%), 19.50 (44%), and 19.61 (42%), respectively, in group B, but there was no difference between the groups at all visits. Postoperative need for ocular hypotensive drugs did not differ in group A (P = 0.231); however, it was significantly lower in group B (P = 0.027). Group A had 87%, 77%, and 74% success rates at 1, 3, and 6 months, respectively, whereas group B had 91%, 86%, and 77% success rates at 1, 3, and 6 months, respectively. Postoperative complications and intervention did not reveal any statistical difference between the two groups. Conclusion: MP?TSCPC may be considered as a temporizing measure both as a primary or as an additional intervention to control the IOP in eyes with refractory and advanced glaucoma that have a high risk of vision?threatening complications with invasive surgery.

Safety and efficacy of XEN gel drainage tube implantation in the treatment of refractory glaucoma / 国际眼科杂志(Guoji Yanke Zazhi)

AIM: To preliminarily evaluate the efficacy and safety of XEN drainage tube implantation in the treatment of refractory glaucoma.METHODS: The clinical data of 10 patients(11 eyes)with refractory glaucoma who underwent XEN gel drainage tube implantation in Peking University Third Hospital from September 2021 to January 2022 were retrospectively analyzed. All patients were followed-up for 8-12mo after surgery, the intraocular pressure(IOP)and the use of IOP lowering medication were observed, and the effect of the surgery was evaluated.RESULTS: The highest IOP was 21-55(median 35)mmHg before surgery and 10-40(median 15)mmHg at the last follow-up. There were 2-4(median 4)kinds of IOP lowering drugs before operation and 0-4(median 0)kinds of IOP lowering drugs at the last follow-up. Up to the last follow-up, the surgery was successful in 8 eyes and unsuccessful in 3 eyes.CONCLUSION: Implantation of XEN gel drainage tube is a safe and effective method for the treatment of refractory glaucoma.

Safety and efficacy of Aurolab aqueous drainage implant in refractory glaucoma: A prospective study

Purpose: This study was conducted to assess the intraocular pressure (IOP) control and postoperative complications following a non?valved glaucoma drainage device (GDD) surgery in refractory glaucoma. Methods: This was a prospective interventional study conducted on patients with glaucoma refractory to maximal medications or failed surgical treatment who underwent Aurolab aqueous drainage implant (AADI; Aurolabs, India) surgery. Primary outcome measures were IOP control, postoperative complications, and reduction in the number of antiglaucoma medications (AGM). Results: Thirty-four eyes were analyzed and the mean follow?up was 16.06 ± 5.63 months. The preoperative median (Q1, Q3) IOP was 31 mmHg (28, 36.5) which decreased to 12 mmHg (12, 14) at 6 months postoperatively. The median (Q1, Q3) number of AGMs decreased from 3 (3, 4) to 0 (0, 1). Significant complications like implant extrusion and tube exposure were noted in two eyes. The total success and failure rates at 6 months were 91.1% and 8.8%, respectively. Conclusion: AADI is effective in achieving target IOP and significantly reduces the use of AGMs with good safety in the short term. Long?term follow?up studies are needed to assess long?term IOP control and cost?effectiveness.

Outcomes of trabeculectomy in eyes with refractory acute primary angleclosure in Indian eyes

Purpose: To report the outcomes of trabeculectomy in eyes with refractory acute primary angle?closure attack. Methods: Patients with acute primary angle?closure attack and who underwent trabeculectomy for medically uncontrolled intraocular pressure within 2 months of presentation were retrospectively analyzed. Primary outcome was intraocular pressure (IOP). Secondary outcome measures were visual acuity, number of antiglaucoma medication (AGM), complications, and risk factors for failure of trabeculectomy. Results: Thirty?five eyes of 31 patients with median (interquartile range) follow?up of 3 (0.5, 9) years were included in the study. Median age at presentation was 55 (47, 60) years. Median duration of symptoms at presentation was 10 (4, 16) days and median time from presentation to surgery was 13 (6, 25) days. Median IOP reduced from 42 (36, 46) to 13 (12, 16) mmHg (P < 0.001) and median number of AGM reduced from 3 (1, 3) to 0 (0, 0) after trabeculectomy at the end of 1 year. The probability of complete and qualified success was 88% (95% confidence interval [CI]: 72%–95%) and was 97% (95% CI: 81%–99%) at 1 year, respectively. Failure was noted in six eyes. Subsequent cataract surgery was needed in 13 eyes (37%) with a median duration from trabeculectomy being 6.75 (1, 11) years. None of the preoperative, intraoperative, or postoperative factors tested were associated with failure (P > 0.10 for all associations on Cox proportional hazard regression analysis). Conclusion: In medically unresponsive cases of acute primary angle?closure attack, primary trabeculectomy seems safe and effective in Indian eyes

Comparison of the therapeutic effects of high-intensity focused ultrasound cycloplasty and cyclocryotherapy on refractory glaucoma / 国际眼科杂志(Guoji Yanke Zazhi)

@#AIM: To compare the therapeutic effects of high-intensity focused ultrasound cycloplasty(UCP)and cyclocryotherapy on refractory glaucoma.<p>METHODS:This retrospective study included 45 patients(81 eyes)with refractory glaucoma admitted to the hospital between January 2017 and December 2020. According to the treatment method, patients enrolled were divided into cyclocryotherapy group(22 patients, 40 eyes)and high-intensity UCP group(23 patients, 41 eyes). Changes in intraocular pressure at 1d, 1wk, 1 and 3mo after operation were compared between the two groups. The Numerical Rating Scale(NRS)was used to evaluate eyeball pain. Surgical results and complications in the two groups were compared. <p>RESULTS:The total effective rate of operation in the high-intensity UCP group was significantly higher than that in the control group(<i>P</i><0.05). Generalized estimation equation analysis showed that there were statistically significant differences in intraocular pressure and eyeball pain between the two groups before and after operation(all <i>P</i><0.05). There were statistically significant differences in intraocular pressure and eyeball pain between the two groups at different time points after operation(all <i>P</i><0.05). The incidence rates of complications such as conjunctival hyperemia, corneal edema, anterior chamber inflammatory exudation, reactive intraocular hypertension and hyphema in the high-intensity UCP group were significantly lower than those in the cyclocryotherapy group(<i>P</i><0.05).<p>CONCLUSION: High-intensity UCP is effective in the treatment of refractory glaucoma, with obvious advantages in reducing intraocular pressure, eyeball pain and complications as compared with cyclocryotherapy.

Allogeneic corneal stromal flap applied in implantation of Ahmed glaucoma valve / 中华显微外科杂志

Objective:To investigate the effectiveness and safety of the allogeneic corneal stromal flap in reducing the exposure of the drainage catheter in the implantation of Ahmed glaucoma valve.Methods:Fifty-three patients(61 eyes) with refractory glaucoma treated by Ahmed glaucoma valve implantation from January 2017 to April 2019 were retrospectively analysed. The patients were divided into sclera tunnel group(routine group) and sclera tunnel with allogeneic corneal stroma flap covering(improved group). The cumulative success rate of surgery, preoperative intraocular pressure(IOP), IOP at the last outpatient follow-up, the best-corrected visual acuity(BCVA), BCVA at the last outpatient follow-up, drainage catheter exposure and other surgical complications were collected from both groups at 6, 12 and 24 months after surgery. The data between the 2 groups were statistically analyzed, P<0.05 was statistically significant. Results:The cumulative success rates of 6, 12 and 24 months after operation were 89.7%, 86.2% and 69.0% in the routine group, and 90.6%, 90.6% and 71.8% in the improved group, respectively. There was no significant differences between the 2 groups( P>0.05). The IOP and BCVA at the final follow-up were significantly improved in both groups, with a statistical significant difference( P<0.05). In the conventional group, the exposure of drainage catheter occurred in 4 eyes(13.8%). Further surgeries were carried out to cover the exposed drainage catheters with allogeneic corneal stroma flaps and amniotic membrane and all had good recovery. There was no drainage catheter exposure in the improved group. The difference between the 2 groups was statistically significant( χ2=4.724, P=0.030). There was no significant difference in other surgical complications between the 2 groups( χ2=0.160, P=0.689). No intraoperative or postoperative complications regarding the corneal stromal flap were observed. Conclusion:Implantation of Ahmed glaucoma valve with allogeneic corneal stromal flap sealing can effectively reduce the exposure of the drainage catheter. It is a safe method.

Research progress in ultrasound cycloplasty for the treatment of glaucoma / 中华实验眼科杂志

Surgery to destroy the ciliary body is an effective means to reduce the intraocular pressure in glaucoma.Ultrasound cycloplasty (UCP) is a computer-aided automatic operation that produces high-intensity focused ultrasound to induce ciliary body coagulation through miniaturized transducers.UCP reduces intraocular pressure mainly by destroying ciliary process epithelial cells and increasing uveoscleral outflow.With a wide range of indications, UCP is mainly used for refractory glaucoma, including patients with or without history of anti-glaucoma surgery.It can reduce intraocular pressure safely and efficiently with good outcome, and can be used as a reproducible effective alternative to non-invasive glaucoma surgery.The effect of UCP is better in patients with angle-closure glaucoma, high intraocular pressure before operation, application of second-generation probe and long exposure time.In order to provide reference for clinical treatment and research, the indications, surgical procedures, precautions, mechanism of action, effectiveness, safety, factors affecting therapeutic effect and the deficiencies of researches about UCP in the treatment of glaucoma were reviewed in this article.

Implante de la válvula de Baerveldt en un caso con glaucoma refractario / Baerveldt valve implantation in a case of refractory glaucoma

Se presenta una paciente femenina, de 52 años de edad, con antecedentes de asma bronquial, miopía y glaucoma juvenil diagnosticado a los 22 años de edad. Le fueron realizadas dos trabeculectomías en el ojo izquierdo y una en el ojo derecho. En el año 2008 se le realizó cirugía de facoemulsificación más implante de lente intraocular en ambos ojos. La paciente acudió a nuestro Servicio hace un año, y refirió disminución progresiva de la visión. El examen oftalmológico reveló agudeza visual mejor corregida de 0,4 y presión intraocular de 30 y 23,5 mm/Hg para los respectivos ojos, con terapia hipotensora máxima tolerable. Al fondo de ojo se observó daño glaucomatoso avanzado, mayor en ojo izquierdo. Como opción de tratamiento se realizó ciclofotocoagulación transescleral en 2 cuadrantes del ojo derecho. A los 6 meses se constató presión intraocular de 30 y 18 mm/Hg, y se decidió el implante de la válvula de Baervelt en el temporal superior del ojo derecho. En el posoperatorio a los 7 días el examen oftalmológico arrojó presión intraocular de 5 mm/Hg, atalamia grado III y agudeza visual mejor corregida de 0,2. Se prescribió tratamiento con midriático ciclopléjico y antinflamatorios tópicos y sistémicos, y se logró a los 15 días mejoría del cuadro ocular. Se obtuvo buena agudeza visual y presión intraocular de 12 mmHg a los 3 meses del posoperatorio. El dispositivo del drenaje de Baerveldt es eficaz para lograr la reducción de la presión intraocular en el glaucoma refractario(AU)

A case is presented of a female 52-year-old patient with a history of bronchial asthma, myopia and juvenile glaucoma diagnosed at age 22. Two trabeculectomies were performed on the left eye and one on the right eye. In the year 2008 the patient underwent phacoemulsification surgery plus intraocular lens implantation in both eyes. She attended our service a year ago, reporting progressive vision reduction. Ophthalmological examination revealed best corrected visual acuity of 0.4 and intraocular pressure of 30 and 23.5 mm/Hg for either eye, with maximum tolerated hypotensive therapy. Funduscopy showed advanced glaucomatous damage, greater in the left eye. The treatment option selected was transcleral cyclophotocoagulation in two quadrants of the right eye. At 6 months intraocular pressure was 30 and 18 mm/Hg, and it was decided to implant a Baerveldt valve in the upper temporal quadrant of the right eye. Ophthalmological examination results at 7 days postoperative were intraocular pressure 5 mm/Hg, grade III athalamia and best corrected visual acuity 0.2. The treatment indicated was a cycloplegic mydriatic and topical and systemic anti-inflammatories. Ocular status improvement was achieved at 15 days. Satisfactory visual acuity and an intraocular pressure of 12 mm/Hg were obtained at 3 months postoperative. The Baerveldt drainage device is effective to achieve intraocular pressure reduction in refractory glaucoma(AU)

Pars plana placement of Ahmed glaucoma valve tube through sclerotomy port in refractory glaucoma: A novel surgical technique

We describe a case of 34-year-old male with post penetrating keratoplasty glaucoma, post trabeculectomy with aphakia in the only seeing eye, in which a modified surgical technique of inserting Ahmed glaucoma valve (AGV) tube in vitreous cavity was done to reduce the risks associated with pars plana incision during pars plana vitrectomy (PPV). A hybrid 20-25 gauge PPV was done concurrently, implant fixed to sclera, and tube inserted through the 25 gauge sclerotomy port in supero-temporal quadrant. Visual acuity and intraocular pressure remained stable during 1-year follow-up.

Resultados de la válvula de Ahmed en el glaucoma refractario pediátrico / Results of Ahmed valve implantation in pediatric refractory glaucoma

RESUMEN Objetivo: Determinar los resultados del implante dispositivo de glaucoma de Ahmed en pacientes con glaucoma pediátrico refractario. Métodos: Se realizó un estudio de serie de casos en 15 pacientes (17 ojos) con glaucoma pediátrico refractario atendidos en el Servicio de Oftalmología Pediátrica del Instituto Cubano de Oftalmología "Ramón Pando Ferrer" de enero del año 2011 a enero de 2016, a quienes se les implantó una válvula de Ahmed y fueron seguidos por un periodo de 3 años. Se evaluaron la agudeza visual, la presión intraocular pre y posoperatoria, el éxito completo, el éxito calificado, las complicaciones y las reintervenciones. Resultados: La mediana de edad de los pacientes fue de 4,0 años y predominó el sexo masculino (58,8 por ciento). La media de la presión intraocular preoperatoria fue de 37,3 mmHg y disminuyó a 19,4 mmHg de manera significativa (p= 0,000) en el posoperatorio. El análisis de supervivencia global mostró una probabilidad acumulada de éxito completo de 94,1 por ciento al 1,5 mes, 70,6 por ciento a los 12 meses, 58,8 por ciento a los 18 meses, y 47,1 por ciento a los 24 y a los 36 meses. La de éxito calificado fue de: 94,1 por ciento a los 12 meses, 82,4 por ciento a los 18 meses, y 76,5 por ciento a los 24 y a los 36 meses. La frecuencia de complicaciones fue de 29,4 por ciento y la de reintervenciones de 23,5 por ciento. Conclusiones: El implante de válvula de Ahmed en el glaucoma pediátrico refractario es una indicación para la reducción de la presión intraocular(AU)

ABSTRACT Objective: Determine the results of Ahmed glaucoma valve implantation in patients with pediatric refractory glaucoma. Methods: A case-series study was conducted of 15 patients (17 eyes) with pediatric refractory glaucoma attending the pediatric ophthalmology service of Ramón Pando Ferrer Cuban Institute of Ophthalmology from January 2011 to January 2016. These patients underwent Ahmed valve implantation and were followed up for a period of three years. Evaluation was performed of visual acuity, pre- and post-operative intraocular pressure, complete success, qualified success, complications and reinterventions. Results: Mean age of patients was 4.0 years, with a predominance of the male sex (58.8 percent). Mean preoperative intraocular pressure was 37.3 mmHg, significantly decreasing to 19.4 mmHg (p= 0.000) in the postoperative period. Overall survival analysis revealed a cumulative probability of complete success of 94.1 percent at 1.5 months, 70.6 percent at 12 months, 58.8 percent at 18 months and 47.1 percent at 24 and 36 months. Cumulative probability of qualified success was 94.1 percent at 12 months, 82.4 percent at 18 months and 76.5 percent at 24 and 36 months. The rate of complications and reinterventions was 29.4 percent and 23.5 percent, respectively. Conclusions: Indication of Ahmed valve implantation in pediatric refractory glaucoma is aimed at reducing intraocular pressure(AU)

Clinical outcome of a nonvalved Aurolab aqueous drainage implant in posterior segment versus anterior chamber

Purpose: To evaluate the outcome of a nonvalved Aurolab aqueous drainage implant (AADI) in the management of refractory glaucoma. Methods: Retrospective case series of patients with refractory glaucoma underwent AADI implantation in posterior segment (PS group) or anterior chamber (AC group) with minimum follow-up of 1 year. Primary outcome criterion was success, defined as intraocular pressure (IOP) <18 or >6 mm Hg or IOP reduced to <20% from baseline, for two consecutive visits after 3 months. Failure was defined as inability to meet IOP criteria, any additional glaucoma surgery, loss of light perception, and implant explantation. Secondary outcome criteria compared groups based on mean IOP, mean glaucoma medication use, best-corrected visual acuity, and complications at each postoperative visit. Results: In the AC and PS group of 64 patients, 32 tubes each were placed. Preoperative mean IOP was 37.41 ± 8.6 and 43.38 ± 10.3 mm Hg in AC and PS, respectively. Postoperatively IOP reduced to 14.22 ± 4.9 and 15.21 ± 8.1 mm Hg in AC and PS groups, respectively (P < 0.001). Preoperative mean antiglaucoma medication changed from 2.56 ± 0.9 and 3.44 ± 0.5 to 1.03 ± 0.9 and 1.67 ± 0.5 in AC and PS, respectively, postoperatively (P < 0.001). No significant change in VA was noted in either group. At 12 months, success rate was 84% in AC group and 72% in PS group, with PS group having 2.63 times higher hazard (risk) of failure than AC group. Conclusion: AADI implantation in PS or AC is a safe and effective method for IOP control in refractory glaucoma with its low cost being of significance in developing countries.

Clinical observation of modified Ahmed glaucoma valve implantation in the treatment of refractory glaucoma / 国际眼科杂志(Guoji Yanke Zazhi)

@#AIM: To compare the clinical efficacy of two methods for treating refractory glaucoma.<p>METHODS: A total of 30 patients with refractory glaucoma(32 eyes)selected from our hospital from January 2014 to September 2018 were retrospectively analyzed. According to the treatment methods, they were divided into experimental group(16 eyes treated by modified Ahmed glaucoma valve implantation)and control group(16 eyes treated by traditional Ahmed glaucoma valve implantation). The visual acuity, intraocular pressure, number of anti-glaucoma drugs, the success rate, complications and average length of hospitalization were compared between the two groups, during follow-up at post operative 1d, 1wk, 1mo, 3mo and 6mo.<p>RESULTS:There was no significant difference in intraocular pressure between the two groups at post-operative 1d, 1wk, 1mo, 3mo, 6mo(all <i>P</i>>0.05). The total success rate was 87%(14/16)in experimental group while 75%(12/16)in control group(<i>P</i>=0.654). BCVA did not improve significantly at post operative 6 mo compared with baseline in both groups(<i>P</i>>0.05). The average length of hospital stay in the experimental group(4.50±1.37d)was significantly lower than that in the control group(7.63±3.69d)(<i>P</i>=0.003). The incidece of shallow anterior chamber was 31% in control group, while in experimental group, it was 0, which showed significant difference.<p>CONCLUSION: Modified Ahmed drainage valve implantation is an effective method for treating refractory glaucoma, with more simple operations, shorter hospitalizing time and lower incidence of shallow anterior chamber.

Comparison of efficacy and safety of two different parameters of transscleral cyclophotocoagulation / 国际眼科杂志(Guoji Yanke Zazhi)

@#AIM:To compare the efficacy of transscleral cyclophotocoagulation(TSCP)with two different laser parameters.<p>METHODS: A total of 46 cases with refractory glaucoma(46 eyes)who underwent TSCP from January 2014 to December 2018 were analyzed retrospectively. According to the laser parameters, all cases were divided into low-power group(treated by low-power TSCP)and conventional parameter group(treated by conventional parameter TSCP). Intraocular pressures(IOP), best-corrected visual acuity(BCVA), number of anti-glaucoma drugs and complications were observed and compared between the two groups.<p>RESULTS: There was no significant difference of IOP between the two groups at postoperative 1d, 1wk, 1mo and 3mo(all <i>P</i>>0.05). The total success rate was 87% in the low-power group while 83% in the conventional parameter group(<i>P</i>=1.000).The overall incidence of complications of the low-power group(39%)was lower than that of the conventional parameter group(78%)(<i>P</i>=0.007)at postoperative 3mo. The early postoperative pain score of the low-power group was significantly lower than that of the conventional parameter group(<i>P</i>=0.007).<p>CONCLUSION:Compared with conventional parameters, TSCP with lower power may reduce IOP similarly with less pain and fewer complications.

Éxito y seguridad de la resección de quiste encapsulado en implante valvular de Ahmed. Serie de casos / Success and safety of encapsulated cyst resection in Ahmed valve implant: case series

Introducción: el encapsulamiento de la ampolla o también llamado "quiste de Tenon" alrededor del dispositivo puede comprometer el funcionamiento valvular, aumentando la presión intraocular y así requiriendo procedimientos quirúrgicos adicionales. Objetivo: describir la eficacia y seguridad de la resección de quiste encapsulado en implante valvular de Ahmed en el control de la presión intraocular. Diseño de estudio: estudio observacional, retrospectivo, serie de casos. Método: se hizo un análisis de los pacientes a los que se les realizó resección de quiste encapsulado con un seguimiento a 6 meses, se excluyeron pacientes con antecedente de procedimiento ciclodestructivo, agudeza visual no percepción de luz, alteración del estado de conciencia, cirugía combinada y /o seguimiento postoperatorio menor de 3 meses. Resultados: se analizaron 14 ojos de los cuales 9 (64.3%) eran mujeres. El promedio de edad fue 56.1 con un rango entre 14 ­ 83 años. La presión intraocular preoperatoria promedio fue 26.7± 6.6 mmHg con una reducción estadísticamente significativa desde el primer día posoperatorio 9.8 ± 0.93 mmHg y al sexto mes 13.7 ± 0.94 mmHg (p 0.005). En el primer mes posoperatorio se logró reducción significativa en el número de medicamentos hipotensores (p 0.003), el cual se estabilizó al tercer mes y al sexto mes no presentó diferencia estadísticamente significativa (p 0.078). Conclusión: la resección de quiste encapsulado es un procedimiento efectivo para lograr el control de la presión intraocular en pacientes con glaucomas refractarios y/o no controlados con pocas complicaciones asociadas.

Background: the encapsulation of the bleb or so-called (Tenon cyst) around the device can compromise valve function, increasing intraocular pressure and thus requiring additional surgical procedures. Objective: to describe the efficacy and safety of encapsulated cyst resection in Ahmed valve implant for the control of intraocular pressure. Study design: observational study, retrospective cases series. Method: an analysis was made of the patients who underwent encapsulated cyst resection between January 2016 and August 2017 with a 6-month follow-up, patients with a history of cyclodestructive procedure, visual acuity of no light perception, altered state of consciousness, combined surgery and / or postoperative follow-up of less than 3 months were excluded. Results: 14 eyes were analyzed, of which 9 (64.3%) were women. The average age was 56.1 with a range between 14 - 83 years. he average preoperative intraocular pressure was 26.7 ± 6.6 mmHg with a statistically significant reduction from the first postoperative day 9.8 ± 0.93 mmHg and at the sixth month 13.7 ± 0.94 mmHg (p 0.005). In the fi rst postoperative month there was a significant reduction in the number of hypotensive drugs (p 0.003), which stabilized at the third month and at the sixth month did not present a statistically significant difference (p 0.078). Conclusion: encapsulated cyst resection is an effective procedure to achieve control of intraocular pressure in patients with refractory and / or uncontrolled glaucoma with few associated complications.

A prospective randomized controlled study of Aurolab aqueous drainage implant versus Ahmed glaucoma valve in refractory glaucoma: A pilot study

Purpose: To study the efficacy of the Aurolab aqueous drainage implant (AADI) compared to Ahmed glaucoma valve (AGV) in patients with refractory glaucoma. Methods: This was a prospective, randomized controlled trial. Thirty-eight adult patients (>18 years) scheduled for a glaucoma drainage device (GDD) were randomized into two groups to receive either AGV or AADI. Primary outcome measures: intraocular pressure (IOP) control and requirement of antiglaucoma medications; secondary outcome measures: final best correct visual acuity (log MAR), visual field (Visual field index [VFI], mean deviation [MD] and pattern standard deviation [PSD]), postoperative complications and additional interventions. Complete success was defined as IOP ?5–?18 mmHg without antiglaucoma medications/laser/additional glaucoma surgery or any vision threatening complications. Results: There were 19 age and sex-matched patients in each group. Both groups had comparable IOP before surgery (P = 0.61). The AGV group had significantly lower IOP compared to AADI group (7.05 ± 4.22 mmHg vs 17.90 ± 10.32 mmHg, P = <0.001) at 1 week. The mean postoperative IOP at 6 months was not significantly different in the two groups (13.3 ± 4.2 and 11.4 ± 6.8 mmHg respectively; P = 0.48). At 6 months, complete success rate according to antiglaucoma medication criteria was 78.94% in AADI and 47.36% in AGV groups. AGV group required 1.83 times more number of topical medications than AADI group. There was no significant difference in early (P = 0.75) and late (P = 0.71) postoperative complications in the AADI and AGV group. The complete success rate was higher in AADI group (68.42%) than AGV group (26.31%) (P = 0.034). Conclusion: In this study, AADI appears to have comparable efficacy versus AGV implant with higher complete success rate at 6 months follow-up.

Combined cataract extraction with a new nonvalved glaucoma drainage device in adult eyes with cataract and refractory glaucoma

Purpose: The purpose of the study is to report the outcomes of simultaneous cataract extraction (CE) and a new nonvalved glaucoma drainage device (GDD), Aurolab Aqueous Drainage Implant (AADI), in eyes with cataract and refractory glaucoma. Methods: This was a non-comparative, interventional, retrospective study. Consecutive patients who underwent AADI together with phacoemulsification from June-2015 to January-2017 by a single fellowship trained glaucoma surgeon with documented 3-months of follow-up were included. The main outcomes were intraocular pressure (IOP), antiglaucoma medication (AGM), visual acuity, and complications. Results: We included 19 eyes of 17 patients with average follow-up of 14.4 ± 8.4 months. IOP and AGM reduced from 36.9 ± 11.1 mmHg and 4 ± 0.8 preoperatively to 12 ± 4.5 mmHg and 0.8 ± 1.2, respectively (P < 0.001). Complications were seen in seven eyes (36.8%). Total success was seen in 17 eyes (89.5%). None of the patients lost vision. Conclusion: Combining cataract extraction with the new non-valved Aurolab Aqueous Drainage Implant, appears to be an effective and safe technique in eyes with refractory glaucoma and cataract. Larger studies and further follow-up is recommended for such patients.

Efficacy of Bevacizumab combined with EX-PRESS in the treatment of refractory glaucoma / 国际眼科杂志(Guoji Yanke Zazhi)

·AIM: To investigate the efficacy of Bevacizumab intravitreal injection combined with EX- PRESS in the treatment of refractory glaucoma. ·METHODS: The research objects were 150 cases (150 eyes) of patients with refractory glaucoma from June 2014 to December 2016 in our hospital. All patients were treated with EX - PRESS glaucoma drainage device implantation, and their medicine data were analyzed retrospectively. Totally 70 cases (70 eyes) were treated with EX-PRESS only were set as the control group; 80 cases (80 eyes) received bevacizumab intravitreal injection on the basis of the treatment of the control group were set as the observation group. The successful rate of operation was evaluated, the intraocular pressure was measured before operation and at 7d, 1, 3, 6mo after treatment by non-contact conometer, followed by record of the visual acuity and complications before and after 6mo of treatment. · RESULTS: The observation group's total surgical success rate was 72.5%, which was sharply higher than that of the control group (58. 6%); while the partial success rate was 17. 5%, which was significantly lower than that of the control group (30.0%), with statistical significance (χ2=5.453, P=0.028; χ2=4.213, P=0.047). Two groups'surgical failure rate had no distinct difference (χ2=0.000,P=1.000). There was no significant difference in visual acuity of the two groups before and after operation (P>0.05). There was no significant difference in intraocular pressure between the two groups (Fgroups=982.27,P<0.05; Ftime=941.88, P<0.05). The intraocular pressure of the two groups decreased significantly after treatment, and at the 7d observation group was significantly higher than that of the control group after operation (P<0.05). After 1, 3, 6mo of operation, there was no abvious difference between two groups on IOP (P> 0. 05). The observation group's low intraocular pressure,anterior chamber bleeding and shallow anterior chamber incidence were significantly lower than those of the control group, there was statistical meaning (P<0.05). · CONCLUSION: Intravitreal injection of bevacizumab combined with EX-PRESS in the treatment of refractory glaucoma can improve the complete success rate,as well as perform effective control on complications such as short - term intraocular pressure, hyphema, low intraocular pressure.

A novel modified scleral tunnel prevents tube exposure in Ahmed valve implantation / 眼科新进展

Objective To evaluate the effectiveness and safety of modified scleral tunnel for the prevention of Ahmed valve tube exposure in Ahmed valve implantation for refractory glaucoma.Methods A retrospective study was conducted in 72 patients with Ahmed glaucoma valve implantation for refractory glaucoma.All the patients were divided into unmodified and modified scleral tunnel group.In the unmodified scleral tunnel group,38 patients (38 eyes) underwent traditional scleral tunnel in Ahmed valve implantation,while in the modified scleral tunnel group,34 patients (34 eyes) received modified scleral tunnel in the procedures.The changes in intraocular pressure and visual acuity after operation were observed,and the incidence of drainage tube exposure and other complications were compared between the two methods after Ahmed valve implantation.The patients were followed up for 6 to 36 months with an average of 18 months.Results The intraocular pressure was (16.30 ±5.73) mmHg (1kPa =7.5 mmHg) in the unmodified scleral tunnel group and (15.80 ± 6.12)mmHg in the modified scleral tunnel group,with no significant difference between the two groups (P ＞ 0.05),but there was significant difference with the preoperative data (48.4 ± 5.79) mmHg (P ＜ 0.01).During the follow-up,conjunctival tube exposure was seen in 3 eyes (7.9％) in the unmodified scleral tunnel group,whereas there was no tube exposure in the modified scleral tunnel group.Conclusion The modified scleral tunnel is capable to prevent conjunctival tube exposure in patients with refractory glaucoma,which is more efficient and safe than traditional scleral tunnel in Ahmed glaucoma valve implantation.